Myoclonic dystrophy: Decoding a “genetic time bomb”

Presented by

Fatai Akemokwe, MBBS, FWACP

Clinical Neurophysiology Fellow

University of Kentucky

And

Extended-window tenecteplase: From time-based to perfusion-based selection

Presented by

Georgia Rubinowicz, DO

Vascular Neurology Fellow

University of Kentucky

Tuesday, June 2, 2026

8:00 - 8:50 AM EDT

Zoom only: https://uky.zoom.us/j/81485627103

Upon completion of this activity, participants will be able to:

1. Distinguish between the two types of myotonic dystrophy (DM)
2. Describe the genetics and pathophysiology of DM
3. Diagnose DM using genetic and neurophysiological tools
4. Develop a comprehensive, multidisciplinary, patient-centered management plan for DM
5. Outline the scientific basis for replacing time-based eligibility with perfusion imaging criteria in the selection of patients for intravenous thrombolysis.
6. Determine imaging eligibility for extended-window tenecteplase using CT perfusion mismatch parameters.
7. Identify eligible patients using the 2026 AHA/ASA guideline recommendations for extended-window thrombolysis.

Disclosure of Financial Interest Summary

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.